BioLineRx Announces $10 Million Registered Direct Offering

Core Points - BioLineRx Ltd. has entered into definitive agreements for the purchase of 50,000,000 American Depositary Shares (ADSs) and accompanying warrants at a price of $0.20 per ADS, with the offering expected to close around January 7, 2025 [1][3] - The gross proceeds from the offering are anticipated to be approximately $10 million, which will be used for research and development, expanding the drug pipeline, and general corporate purposes [3] - H.C. Wainwright & Co. is acting as the exclusive placement agent for this offering [2] Company Overview - BioLineRx is a biopharmaceutical company focused on developing therapies for oncology and rare diseases, with its first approved product being APHEXDA® for stem cell mobilization in multiple myeloma [6] - The company utilizes its expertise in development, regulatory affairs, manufacturing, and commercialization to advance its innovative pipeline [6] Offering Details - The offering is made under a "shelf" registration statement filed with the SEC, and the securities will be offered only by means of a prospectus [4] - Each ADS represents fifteen ordinary shares of BioLineRx, with the warrants exercisable immediately upon issuance and expiring five years from the initial exercise date [1]